A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer

Investigational New Drugs

Volumn 21, Issue 1, 2003, Pages 75-84

  Dees, E Claire ^a   Rowinsky, Eric K ^b   Noe, Dennis A ^c   O'Reilly, Seamus ^d   Adjei, Alex A ^e   Elza Brown, Kathy ^f   Donehower, Ross C ^f,g  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b CTRC Institute for Drug Development   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WATERFORD REGIONAL HOSPITAL   (Ireland)

^e MAYO CLINIC   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acridine; Dose escalation; Pharmacokinetics; Pyrazole; Sequence

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; CISPLATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG STRUCTURE; DRUG TOLERANCE; FATIGUE; FEMALE; FEVER; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOKALEMIA; MALE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN MANIFESTATION; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

ACRIDINES; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; FILGRASTIM; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PYRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 0038015345     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022924511602     Document Type: Article

References (12)

1. Capps D, Ross-Kesten S, Shillis J et al.: 2-aminoalkyl-5-nitropyrazolo-[3,4,5-kl]acridines, a new class of anticancer agents (Abstract). Proc AACR 27: 277, 1986
2. Sebolt JS, Scavone SV, Pinter CD, Hamelehle KL, Von Hoff DD, Jackson RC: Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro. Cancer Res 47: 4299-4304, 1987
3. Sebolt JS, Havlick M, Hamelehle K, Nelson J, Leopold W, Jackson R: Activity of the pyrazoloacridines against multidrug-resistant tumor cells. Cancer Chemother Pharmacol 24: 219-224, 1989
4. Jackson RC, Sebolt JS, Shillis JL, Leopold WR: The pyrazoloacridines: approaches to the development of a carcinoma-selective cytotoxic agent. Cancer Invest 8(1): 39-47, 1990
5. Adjei AA, Charron M, Rowinsky EK, Svingen PA, Miller J, Reid JM, Sebolt-Leopold J, Ames MM, Kaufmann SH: Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin Cancer Res 4: 683-691, 1998
6. Clinical Brochure: Pyrazoloacridine. NSC 366140. Bethesda, MD, Division of Cancer Treatment, NCI, December 1990
7. LoRusso P, Foster BJ, Poplin E, McCormick J, Kraut M, Flaherty L, Heilbrun LK, Valdivieso M, Baker L: Phase I clinical trial of pyrazolozcridine NSC366140 (PD 115934). Clin Cancer Res 1(12): 1487-1493, 1995
8. Rowinsky EK, Noe DA, Grochow LB, Sartorius SE, Boling MK, Chen T-L, Lubejko B, Kaufmann SH, Done-hower RC: Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on singledosing and multiple dosing schedules. J Clin Oncol 13: 1975-1984, 1995
9. Adjei AA, Budihardjo II, Rowinsky EK, Kottke TJ, Svingen PA, Buckwalter CA, Grochow LB, Donehower RC, Kaufmann SH: Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal. Clin Cancer Res 3: 761-770, 1997
10. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE: Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9(9): 1692-1703, 1991
11. Rowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen TL, Peereboom D, Bowling MK, Sartorius SE, Ettinger DS, Forastiere AA, Donehower RC: Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 14 (12): 3074-3084, 1996
12. Zalupski MM, Phillip PA, LoRusso P, Shields AF: Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma. Cancer Chemother Pharmacol 40(3): 225-227, 1997